395 Enhancement of bispecific T cell engagers (bispecific TCE) killing potency in AML with the neximmune artificial immune modulation (AIM™) adoptive cell therapy (ACT) T cells

• Rui Wang,
• Adam Parks,
• Mathias Oelke,
• Shweta Jain,
• Ruipeng Wang,
• Sojung Kim,
• Jack Ragheb,
• Charles Reed,
• Brian Alvarez,
• Jerome Zeldis,
• Daniel Bednarik

Affiliations

Rui Wang

Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, China

Adam Parks

1 Department of Emergency Medicine, University of Ottawa, Ottawa, Ontario, Canada

Mathias Oelke

Aff4 grid.21107.350000 0001 2171 9311Johns Hopkins School of Medicine, Department of PathologyInstitute for Cell Engineering Baltimore Maryland USA

Shweta Jain

18Seagen Inc., Late Stage Development, Bothell, USA

Ruipeng Wang

NeImmune, Gaithersburg, MD, USA

Sojung Kim

NeImmune Inc., Gaithersburg, MD, USA

Jack Ragheb

NeImmune, Gaithersburg, MD, USA

Charles Reed

NeImmune, Gaithersburg, MD, USA

Brian Alvarez

NeImmune, Gaithersburg, MD, USA

Jerome Zeldis

NeImmune, Gaithersburg, MD, USA

Daniel Bednarik

NeImmune, Gaithersburg, MD, USA